VALENCIA, Calif., Sept. 18 MannKind Corporation(Nasdaq: MNKD), focused on discovering, developing and commercializingtreatments for diabetes and cancer, announced today that it will present atthe UBS Global Life Sciences Conference on September 25, 2007 at 10:30 AM ETat the Grand Hyatt Hotel in New York, NY.
Interested parties can access a link to the live web cast of thepresentation in the Investor Relations section of the Company's website athttp://www.mannkindcorp.com. A replay of the presentation will be availablefor 14 days.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, developmentand commercialization of therapeutic products for diseases such as diabetesand cancer. Its lead product, the Technosphere(R) Insulin System, iscurrently in phase 3 clinical trials in the United States, Europe and LatinAmerica to study its safety and efficacy in the treatment of diabetes. Formore information on MannKind Corporation and its technology, visithttp://www.mannkindcorp.com.
SOURCE MannKind Corporation